Document Detail


Molecular targeted therapies for renal cell carcinoma.
MedLine Citation:
PMID:  18163945     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
New advances in technology to directly target specific molecular events in the proliferation of cancer have led to promising results in renal cell carcinoma. Response rates in excess of 70% and complete responses in advanced (metastatic) renal cell carcinoma have caused a change in the paradigm of treatment from immunotherapy. Toxicities are significant, but manageable and pushing the toxicity to tolerability may increase the response rate.
Authors:
Sam D Graham; Mary Elizabeth Warden; Jeffrey Lou
Related Documents :
7684185 - Comparative immunohistochemical study of primary and metastatic carcinomas of the liver.
22767265 - Neuroendocrine differentiation does not have independent prognostic value in conservati...
14750765 - Enophthalmos as initial manifestation of occult, mammogram-negative carcinoma of the br...
4079405 - Breast carcinoma metastatic to eyelids: case report and review of the literature.
3314435 - Fibrocystic breast disease.
16570345 - Identification of serum proteins discriminating colorectal cancer patients and healthy ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Canadian journal of urology     Volume:  14 Suppl 1     ISSN:  1195-9479     ISO Abbreviation:  Can J Urol     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-31     Completed Date:  2008-03-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9515842     Medline TA:  Can J Urol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  48-52     Citation Subset:  IM    
Affiliation:
Urologic Specialists of Virginia, Richmond, VA 23225, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Humans
Immunotherapy / methods*
Kidney Neoplasms / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current management of small renal masses.
Next Document:  Medical management of benign prostatic hypertrophy.